Skip to main content
. Author manuscript; available in PMC: 2023 May 23.
Published in final edited form as: J Acquir Immune Defic Syndr. 2021 Nov 1;88(3):290–298. doi: 10.1097/QAI.0000000000002775

Table 4:

Screening tool sensitivity, specificity, PPV, NPV and NNT (Phase 2)

Validation
sample
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
NNT
(95% CI)
OPD and OVC 87.8 (80.9 – 92.5) 62.6 (54.8 – 69.7) 2.4 (1.5 – 3.6) 99.8 (99.6 – 99.9) 43 (28 – 67)
 
OPD only 88.1 (80.8 – 92.8) 69.0 (61.9 – 75.3) 3.7 (2.7 – 5.0) 99.8 (99.6 – 99.9) 28 (20 - 38)
OVC only 83.3 (5.7 – 99.8) 45.6 (32.6 – 59.2) 0.30 (0.1 – 0.8) 99.9 (99.2 – 100) 338 (128 – 897)